-- 根據其母公司華潤醫藥（HKG:3320）4月24日在香港聯交所發布的公告顯示，江中藥業（SHA:600750）2026年第一季淨利潤為3.12億元人民幣，高於去年同期的3.067億元人民幣。 營收則從11.8億元降至10.4億元。
Related Articles
Research
Brookfield Asset Management Price Target Lowered By US$6 at TD
TD Securities lowered its price target on Brookfield Asset Management Ltd. (BAM.TO, BAM) to US$69 from US$75 on Monday.Analyst Cherilyn Radbourne maintained a Buy rating on shares of the Toronto-based global alternative asset manager ahead of its Q1 results on May 8."Amid cautious investor sentiment on the alt managers, BAM offers a highly resilient/diversified FRE-driven earnings profile, anchored in real assets," Radbourne said in a note to clients."BAM has minimal software exposure, and meaningful scale/experience in power, which enables it to offer a truly differentiated AI backbone solution," the analyst said."Upcoming first closes on three flagship funds offer potential catalysts."(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$BAM$BAM.TO
Research
Aclara Resources Upgraded to Outperform at RBC
Aclara Resources Inc. (ARA.TO) was upgraded to Outperform from Sector Perform at RBC Capital Markets.Analyst Andrew D. Wong raised his price target on shares of the rare earth mining company to $6 from $3."We believe Aclara has a strong strategic position as Western-aligned countries are determined to reduce reliance on Chinese rare earth supply, especially for heavy rare earths (HREE)," Wong said in a note to clients."We see continued progress at Aclara's flagship Carina project which was recently validated by the Serra Verde acquisition (similar size, same locale, later stage, compared to Carina) that included a US government-backed offtake including price floors," the analyst said."Aclara also has further optionality with projects in separation, metals processing, and the Chile project that may be permitted by mid-year."
$ARA.TO
Asia
Biocytogen Pharmaceuticals Turns to Profit in Q1
Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.
$HKG:2315